Role of Photodynamic Therapy in Polypoidal Choroidal Vasculopathy

Akaza, Eriko; Yuzawa, Mitsuko; Matsumoto, Yōko; Kashiwakura, Shiho; Fujita, Kyoko; Mori, Ryusaburo

doi:10.1007/s10384-007-0452-3

Cited by 86 publications

(73 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Regarding the treatment modalities for PCV, photodynamic therapy (PDT) has been widely used, resulting in a high frequency of the complete regression of polyps and an improvement in visual acuity. [5][6][7][8][9][10] However, the long-term outcomes of PDT for PCV indicate that frequent recurrences often result in a visual acuity loss. [11][12][13][14] On the other hand, ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA) is a recombinant humanized anti-vascular endothelial growth factor (VEGF) antibody fragment targeting all isoforms of VEGF 15 that has been used extensively for the treatment of AMD.…”

Section: Introductionmentioning

confidence: 99%

Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy

Inoue

Arakawa

Yamane

et al. 2013

Eye

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy

Inoue

Arakawa

Yamane

et al. 2013

Eye

View full text Add to dashboard Cite

“…Photodynamic therapy (PDT) with verteporfin or intravitreal injection of anti-vascular endothelial growth factor (VEGF) has recently been administered for treatment of PCV eyes, and encouraging results have been reported. [5][6][7][8][9][10] Pathogenesis of PCV is not fully understood. However, VEGF may have a role in pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy

Cho

Kim

Lee

et al. 2011

Eye

View full text Add to dashboard Cite

Purpose To compare the effectiveness of intravitreal injection of bevacizumab and ranibizumab in patients with treatment-naïve polypoidal choroidal vasculopathy (PCV). Methods A total of 66 and 60 eyes of 121 consecutive patients who received intravitreal bevacizumab (1.25 mg) or ranibizumab (0.5 mg) injection for treatment of PCV were retrospectively reviewed. After initial three loading injections by month, injection was performed as needed. Main outcome measures included best corrected visual acuity (BCVA), foveal center thickness (FCT) as assessed by spectral domain optical coherence tomography (SD-OCT), and change in polypoidal lesion on indocyanine green angiography (ICGA). Results At 12 months, average number of injections was 4.72±1.84 in the bevacizumab group and 5.52±1.54 in the ranibizumab group. Mean logarithm of the minimum angle of resolution of BCVA from baseline at 12 months after injection improved by 0.11 in the bevacizumab group (P ¼ 0.02) and by 0.14 in the ranibizumab group (P ¼ 0.01). Average FCT decreased from 368±62.48 to 298±40.77 lm in the bevacizumab group (P ¼ 0.01) and from 371±50.79 to 286±36.93 lm in the ranibizumab group (P ¼ 0.01). Polyp regression rate was 24.2% (16 eyes out of 66 eyes) in the bevacizumab group and 23.3% (14 eyes out of 60 eyes) in the ranibizumab group. There was no statistically significant difference in BCVA improvement achieved, FCT improvement achieved, and polyp regression rate between groups. Conclusion Intravitreal injections of bevacizumab and ranibizumab have similar effects in stabilization of visual acuity, macular edema, and regression of polypoidal complex with PCV eyes.

show abstract

“…Photodynamic therapy (PDT) with verteporfin has been shown to be beneficial and safe for the treatment of subfoveal CNV due to AMD [12, 13], pathological myopia [14, 15], idiopathic CNV [16, 17] and PCV [18, 19]. However, the effect of PDT is thought to vary depending on the lesion status [10, 20].…”

Section: Introductionmentioning

confidence: 99%

Comparative Assessment of Photodynamic Therapy for Typical Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A Multicenter Study in Hyogo Prefecture, Japan

et al. 2009

View full text Add to dashboard Cite

Purpose: We aimed to evaluate the effects of photodynamic therapy (PDT) on different phenotypes of age-related macular degenerations (AMD): typical AMD (tAMD) and polypoidal choroidal vasculopathy (PCV). Procedures: 246 eyes from 242 patients (tAMD: 139, PCV: 107 eyes) were recruited. Gender, age, best-corrected visual acuity (BCVA) before treatment, greatest linear dimension before treatment, lesion phenotype and PDT frequency were evaluated for predicting the BCVA at 12 months after PDT using stepwise multiple regression analyses. Additionally, 125 eyes with tAMD and 97 eyes with PCV followed up for more than 12 months after the final PDT were compared for the recurrence period. Results: In the stepwise analysis, a younger age, better pretreatment BCVA, lower PDT frequency, lesions with PCV and a smaller pretreatment greatest linear dimension were all significantly beneficial for a better BCVA at 12 months after PDT. PCV showed a significantly lower PDT frequency and greater improvement in the BCVA than tAMD. The recurrence period of PCV was significantly later than that of tAMD. Conclusions: The phenotype of AMD is significantly correlated with its prognosis after PDT. PCV showed a significantly better response to PDT in terms of BCVA improvement and effect durability.

show abstract

Role of Photodynamic Therapy in Polypoidal Choroidal Vasculopathy

Cited by 86 publications

References 12 publications

Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy

Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy

Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy

Comparative Assessment of Photodynamic Therapy for Typical Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A Multicenter Study in Hyogo Prefecture, Japan

Contact Info

Product

Resources

About